Jeffrey T. Henderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey T. Henderson has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Shudi Huang
Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada
4 shared publicationsAndrew J. Elia
Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
3 shared publications- Andrew M. Rauth
Departments of Medical Biophysics and Radiation Oncology University of Toronto 610 University Ave Toronto Ontario M5G 2M9 Canada
3 shared publications Ashlin Kanawaty
Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario M5S 3M2, Canada
3 shared publications- Chesarahmia Dojo Soeandy
Department of Pharmaceutical Sciences, University of Toronto, Toronto, Canada
3 shared publications - Xiao Yu Wu
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
3 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
From neural loss to regeneration: modulating cell death to enhance pluripotent stem cell graft survival and integration
Cerebrovascular and neurodegenerative diseases rank among the leading causes of death worldwide and represent an increasing socioeconomic burden, particularly in aging populations. Pluripotent stem cell (PSC)-based therapies have emerged as promising strategies for replacing lost neurons and restoring neural circuits in disorders of the central nervous system (CNS). However, major barriers remain, including poor survival, limited integration, and variable functional maturation of transplanted cells. These challenges currently limit the reproducibility and clinical translation of PSC-based therapies. Here, we examine these barriers with a particular focus on ischemic stroke and Parkinson’s disease, two conditions that represent complementary models of acute and chronic neuronal loss and are among the most advanced indications for PSC-based transplantation. We discuss how programmed cell death signaling contributes not only to neuronal loss in these disorders but also to the limited survival of transplanted PSC-derived grafts. Building on this mechanistic framework, we highlight strategies that may improve graft survival and functional integration. Specifically, we propose an integrated approach that combines modulation of programmed cell death pathways, targeted activation of RAS signaling, optimization of mitochondrial health, and use of biocompatible scaffolds to support neuronal maturation and network integration. Together, these strategies provide a conceptual framework for improving the reliability and therapeutic efficacy of PSC-based cell transplantation therapies and accelerating their translation toward clinical application.
- 17 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessFrom neural loss to regeneration: modulating cell death to enhance pluripotent stem cell graft survival and integration
Cerebrovascular and neurodegenerative diseases rank among the leading causes of death worldwide and represent an increasing socioeconomic burden, particularly in aging populations. Pluripotent stem cell (PSC)-based therapies have emerged as promising strategies for replacing lost neurons and restoring neural circuits in disorders of the central nervous system (CNS). However, major barriers remain, including poor survival, limited integration, and variable functional maturation of transplanted cells. These challenges currently limit the reproducibility and clinical translation of PSC-based therapies. Here, we examine these barriers with a particular focus on ischemic stroke and Parkinson’s disease, two conditions that represent complementary models of acute and chronic neuronal loss and are among the most advanced indications for PSC-based transplantation. We discuss how programmed cell death signaling contributes not only to neuronal loss in these disorders but also to the limited survival of transplanted PSC-derived grafts. Building on this mechanistic framework, we highlight strategies that may improve graft survival and functional integration. Specifically, we propose an integrated approach that combines modulation of programmed cell death pathways, targeted activation of RAS signaling, optimization of mitochondrial health, and use of biocompatible scaffolds to support neuronal maturation and network integration. Together, these strategies provide a conceptual framework for improving the reliability and therapeutic efficacy of PSC-based cell transplantation therapies and accelerating their translation toward clinical application.
- 23 August 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (1) , e01648
A Novel Brain Penetrable Nanocarrier Delivers Brain‐Derived Neurotrophic Factor to Treat Alzheimer's Disease
Alzheimer's disease (AD) affects over 50 million people worldwide and is the sixth leading cause of death in North America with no cure and limited disease‐modifying therapies. Brain‐derived neurotrophic factor (BDNF) is a potential therapeutic agent, as it promotes the survival and synaptic plasticity of glutamatergic and GABAergic neurons in brain regions associated with cognitive and emotive decline in AD, and mice lacking BDNF exhibits hippocampal long‐term potentiation (LTP) impairment, reversible with recombinant BDNF. However, the poor blood‐brain barrier (BBB) permeability and pharmacokinetic properties of BDNF limit its clinical use. To address these limitations, a BDNF nanocarrier system is designed using a novel BBB‐permeable terpolymer (TP). This terpolymer‐based nanoparticle system (BDNF‐TPN) with optimized physiochemical properties protects BDNF in circulation and enables sufficient neuronal delivery of BDNF and neuron survival following Aβ exposure in vitro. The biodistribution and safety of BDNF‐TPN are evaluated via imaging, enzyme‐linked immunosorbent assay, hematologic, clinical biochemical, immunotoxicity, and histology tests. Biomarker studies demonstrate BDNF‐mediated neuroprotective signaling in an APP transgenic mouse model following intravenous injection of BDNF‐TPN with reduced apoptosis and neuron inflammation and increased neuronal survival and synaptic plasticity. Improved hippocampal‐dependent contextual learning in APP transgenic Alzheimer's mice is observed as determined by fear‐conditioning assay following two months of weekly treatments.
- 23 August 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (1) , e01648
A Novel Brain Penetrable Nanocarrier Delivers Brain‐Derived Neurotrophic Factor to Treat Alzheimer's Disease
Alzheimer's disease (AD) affects over 50 million people worldwide and is the sixth leading cause of death in North America with no cure and limited disease‐modifying therapies. Brain‐derived neurotrophic factor (BDNF) is a potential therapeutic agent, as it promotes the survival and synaptic plasticity of glutamatergic and GABAergic neurons in brain regions associated with cognitive and emotive decline in AD, and mice lacking BDNF exhibits hippocampal long‐term potentiation (LTP) impairment, reversible with recombinant BDNF. However, the poor blood‐brain barrier (BBB) permeability and pharmacokinetic properties of BDNF limit its clinical use. To address these limitations, a BDNF nanocarrier system is designed using a novel BBB‐permeable terpolymer (TP). This terpolymer‐based nanoparticle system (BDNF‐TPN) with optimized physiochemical properties protects BDNF in circulation and enables sufficient neuronal delivery of BDNF and neuron survival following Aβ exposure in vitro. The biodistribution and safety of BDNF‐TPN are evaluated via imaging, enzyme‐linked immunosorbent assay, hematologic, clinical biochemical, immunotoxicity, and histology tests. Biomarker studies demonstrate BDNF‐mediated neuroprotective signaling in an APP transgenic mouse model following intravenous injection of BDNF‐TPN with reduced apoptosis and neuron inflammation and increased neuronal survival and synaptic plasticity. Improved hippocampal‐dependent contextual learning in APP transgenic Alzheimer's mice is observed as determined by fear‐conditioning assay following two months of weekly treatments.
- Open Access
- 9 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23790
Antiretroviral drug dolutegravir induces inflammation at the mouse brain barriers
Integrase strand transfer inhibitors (INSTIs) based antiretroviral therapy (ART) is currently used as first‐line regimen to treat HIV infection. Despite its high efficacy and barrier to resistance, ART‐associated neuropsychiatric adverse effects remain a major concern. Recent studies have identified a potential interaction between the INSTI, dolutegravir (DTG), and folate transport pathways at the placental barrier. We hypothesized that such interactions could also occur at the two major blood–brain interfaces: blood‐cerebrospinal fluid barrier (BCSFB) and blood–brain barrier (BBB). To address this question, we evaluated the effect of two INSTIs, DTG and bictegravir (BTG), on folate transporters and receptor expression at the mouse BCSFB and the BBB in vitro, ex vivo and in vivo. We demonstrated that DTG but not BTG significantly downregulated the mRNA and/or protein expression of folate transporters (RFC/ SLC19A1 , PCFT/ SLC46A1 ) in human and mouse BBB models in vitro, and mouse brain capillaries ex vivo. Our in vivo study further revealed a significant downregulation in Slc19a1 and Slc46a1 mRNA expression at the BCSFB and the BBB following a 14‐day DTG oral treatment in C57BL/6 mice. However, despite the observed downregulatory effect of DTG in folate transporters/receptor at both brain barriers, a 14‐day oral treatment of DTG‐based ART did not significantly alter the brain folate level in animals. Interestingly, DTG treatment robustly elevated the mRNA and/or protein expression of pro‐inflammatory cytokines and chemokines ( Cxcl1, Cxcl2, Cxcl3, Il6, Il23, Il12 ) in primary cultures of mouse brain microvascular endothelial cells (BBB). DTG oral treatment also significantly upregulated proinflammatory cytokines and chemokine ( Il6, Il1β, Tnfα, Ccl2 ) at the BCSFB in mice. We additionally observed a downregulated mRNA expression of drug efflux transporters ( Abcc1, Abcc4 , and Abcb1a ) and tight junction protein ( Cldn3 ) at the CP isolated from mice treated with DTG. Despite the structural similarities, BTG only elicited minor effects on the markers of interest at both the BBB and BCSFB. In summary, our current data demonstrates that DTG but not BTG strongly induced inflammatory responses in a rodent BBB and BCSFB model. Together, these data provide valuable insights into the mechanism of DTG‐induced brain toxicity, which may contribute to the pathogenesis of DTG‐associated neuropsychiatric adverse effect.
- 9 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23790
Open AccessAntiretroviral drug dolutegravir induces inflammation at the mouse brain barriers
Integrase strand transfer inhibitors (INSTIs) based antiretroviral therapy (ART) is currently used as first‐line regimen to treat HIV infection. Despite its high efficacy and barrier to resistance, ART‐associated neuropsychiatric adverse effects remain a major concern. Recent studies have identified a potential interaction between the INSTI, dolutegravir (DTG), and folate transport pathways at the placental barrier. We hypothesized that such interactions could also occur at the two major blood–brain interfaces: blood‐cerebrospinal fluid barrier (BCSFB) and blood–brain barrier (BBB). To address this question, we evaluated the effect of two INSTIs, DTG and bictegravir (BTG), on folate transporters and receptor expression at the mouse BCSFB and the BBB in vitro, ex vivo and in vivo. We demonstrated that DTG but not BTG significantly downregulated the mRNA and/or protein expression of folate transporters (RFC/ SLC19A1 , PCFT/ SLC46A1 ) in human and mouse BBB models in vitro, and mouse brain capillaries ex vivo. Our in vivo study further revealed a significant downregulation in Slc19a1 and Slc46a1 mRNA expression at the BCSFB and the BBB following a 14‐day DTG oral treatment in C57BL/6 mice. However, despite the observed downregulatory effect of DTG in folate transporters/receptor at both brain barriers, a 14‐day oral treatment of DTG‐based ART did not significantly alter the brain folate level in animals. Interestingly, DTG treatment robustly elevated the mRNA and/or protein expression of pro‐inflammatory cytokines and chemokines ( Cxcl1, Cxcl2, Cxcl3, Il6, Il23, Il12 ) in primary cultures of mouse brain microvascular endothelial cells (BBB). DTG oral treatment also significantly upregulated proinflammatory cytokines and chemokine ( Il6, Il1β, Tnfα, Ccl2 ) at the BCSFB in mice. We additionally observed a downregulated mRNA expression of drug efflux transporters ( Abcc1, Abcc4 , and Abcb1a ) and tight junction protein ( Cldn3 ) at the CP isolated from mice treated with DTG. Despite the structural similarities, BTG only elicited minor effects on the markers of interest at both the BBB and BCSFB. In summary, our current data demonstrates that DTG but not BTG strongly induced inflammatory responses in a rodent BBB and BCSFB model. Together, these data provide valuable insights into the mechanism of DTG‐induced brain toxicity, which may contribute to the pathogenesis of DTG‐associated neuropsychiatric adverse effect.
- Open Access
- 8 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
An efficient low cost means of biophysical gene transfection in primary cells
Efficient, facile gene modification of cells has become an indispensable part of modern molecular biology. For the majority of cell lines and several primary populations, such modifications can be readily performed through a variety of methods. However, many primary cell lines such as stem cells frequently suffer from poor transfection efficiency. Though several physical approaches have been introduced to circumvent these issues, they often require expensive/specialized equipment and/or consumables, utilize substantial cell numbers and often still suffer from poor efficiency. Viral methods are capable of transducing difficult cellular populations, however such methods can be time consuming for large arrays of gene targets, present biohazard concerns, and result in expression of viral proteins; issues of concern for certain experimental approaches. We report here a widely applicable, low-cost (< $100 CAD) method of electroporation, applicable to small (1–10 μl) cell volumes and composed of equipment readily available to the average investigator. Using this system we observe a sixfold increase in transfection efficiency in embryonic stem cell lines compared to commercial devices. Due to efficiency gains and reductions in volume and applied voltage, this process improves the survival of sensitive stem cell populations while reducing reagent requirements for protocols such as Cas9/gRNAs transfections.
- 8 June 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessAn efficient low cost means of biophysical gene transfection in primary cells
Efficient, facile gene modification of cells has become an indispensable part of modern molecular biology. For the majority of cell lines and several primary populations, such modifications can be readily performed through a variety of methods. However, many primary cell lines such as stem cells frequently suffer from poor transfection efficiency. Though several physical approaches have been introduced to circumvent these issues, they often require expensive/specialized equipment and/or consumables, utilize substantial cell numbers and often still suffer from poor efficiency. Viral methods are capable of transducing difficult cellular populations, however such methods can be time consuming for large arrays of gene targets, present biohazard concerns, and result in expression of viral proteins; issues of concern for certain experimental approaches. We report here a widely applicable, low-cost (< $100 CAD) method of electroporation, applicable to small (1–10 μl) cell volumes and composed of equipment readily available to the average investigator. Using this system we observe a sixfold increase in transfection efficiency in embryonic stem cell lines compared to commercial devices. Due to efficiency gains and reductions in volume and applied voltage, this process improves the survival of sensitive stem cell populations while reducing reagent requirements for protocols such as Cas9/gRNAs transfections.
- Open Access
- 26 February 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Cellular transfection using rapid decrease in hydrostatic pressure
Of all methods exercised in modern molecular biology, modification of cellular properties through the introduction or removal of nucleic acids is one of the most fundamental. As such, several methods have arisen to promote this process; these include the condensation of nucleic acids with calcium, polyethylenimine or modified lipids, electroporation, viral production, biolistics, and microinjection. An ideal transfection method would be (1) low cost, (2) exhibit high levels of biological safety, (3) offer improved efficacy over existing methods, (4) lack requirements for ongoing consumables, (5) work efficiently at any scale, (6) work efficiently on cells that are difficult to transfect by other methods, and (7) be capable of utilizing the widest array of existing genetic resources to facilitate its utility in research, biotechnical and clinical settings. To address such issues, we describe here Pressure-jump-poration (PJP), a method using rapid depressurization to transfect even difficult to modify primary cell types such as embryonic stem cells. The results demonstrate that PJP can be used to introduce an array of genetic modifiers in a safe, sterile manner. Finally, PJP-induced transfection in primary versus transformed cells reveals a surprising dichotomy between these classes which may provide further insight into the process of cellular transformation.
- 26 February 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Open AccessCellular transfection using rapid decrease in hydrostatic pressure
Of all methods exercised in modern molecular biology, modification of cellular properties through the introduction or removal of nucleic acids is one of the most fundamental. As such, several methods have arisen to promote this process; these include the condensation of nucleic acids with calcium, polyethylenimine or modified lipids, electroporation, viral production, biolistics, and microinjection. An ideal transfection method would be (1) low cost, (2) exhibit high levels of biological safety, (3) offer improved efficacy over existing methods, (4) lack requirements for ongoing consumables, (5) work efficiently at any scale, (6) work efficiently on cells that are difficult to transfect by other methods, and (7) be capable of utilizing the widest array of existing genetic resources to facilitate its utility in research, biotechnical and clinical settings. To address such issues, we describe here Pressure-jump-poration (PJP), a method using rapid depressurization to transfect even difficult to modify primary cell types such as embryonic stem cells. The results demonstrate that PJP can be used to introduce an array of genetic modifiers in a safe, sterile manner. Finally, PJP-induced transfection in primary versus transformed cells reveals a surprising dichotomy between these classes which may provide further insight into the process of cellular transformation.
- Open Access
- 24 July 2023
- Published by AccScience Publishing in Advanced Neurology
- Vol. 2023 (2) , 3
Transient receptor potential melastatin 7 signaling in U251 cell migration and invasion involves calcineurin
AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.
- 24 July 2023
- Published by AccScience Publishing in Advanced Neurology
- Vol. 2023 (2) , 3
Open AccessTransient receptor potential melastatin 7 signaling in U251 cell migration and invasion involves calcineurin
AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.
- Open Access
- 1 July 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1857
Dysregulation of Amino Acid Transporters in a Rat Model of TLR7-Mediated Maternal Immune Activation
Maternal immune activation (MIA) during pregnancy is linked to neurodevelopmental disorders in humans. Similarly, the TLR7 agonist imiquimod alters neurodevelopment in rodents. While the mechanisms underlying MIA-mediated neurodevelopmental changes are unknown, they could involve dysregulation of amino acid transporters essential for neurodevelopment. Therefore, we sought to determine the nature of such transporter changes in both imiquimod-treated rats and human placentas during infection. Pregnant rats received imiquimod on gestational day (GD)14. Transporter expression was measured in placentas and fetal brains via qPCR (GD14.5) and immunoblotting (GD16). To monitor function, fetal brain amino acid levels were measured by HPLC on GD16. Gene expression in the cortex of female fetal brains was further examined by RNAseq on GD19. In human placentas, suspected active infection was associated with decreased ASCT1 and SNAT2 protein expression. Similarly, in imiquimod-treated rats, ASCT1 and SNAT2 protein was also decreased in male placentas, while EAAT2 was decreased in female placentas. CAT3 was increased in female fetal brains. Consistent with this, imiquimod altered amino acid levels in fetal brains, while RNAseq demonstrated changes in expression of several genes implicated in autism. Thus, imiquimod alters amino acid transporter levels in pregnant rats, and similar changes occur in human placentas during active infection. This suggests that changes in expression of amino acid transporters may contribute to effects mediated by MIA toward altered neurodevelopment.
- 1 July 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1857
Open AccessDysregulation of Amino Acid Transporters in a Rat Model of TLR7-Mediated Maternal Immune Activation
Maternal immune activation (MIA) during pregnancy is linked to neurodevelopmental disorders in humans. Similarly, the TLR7 agonist imiquimod alters neurodevelopment in rodents. While the mechanisms underlying MIA-mediated neurodevelopmental changes are unknown, they could involve dysregulation of amino acid transporters essential for neurodevelopment. Therefore, we sought to determine the nature of such transporter changes in both imiquimod-treated rats and human placentas during infection. Pregnant rats received imiquimod on gestational day (GD)14. Transporter expression was measured in placentas and fetal brains via qPCR (GD14.5) and immunoblotting (GD16). To monitor function, fetal brain amino acid levels were measured by HPLC on GD16. Gene expression in the cortex of female fetal brains was further examined by RNAseq on GD19. In human placentas, suspected active infection was associated with decreased ASCT1 and SNAT2 protein expression. Similarly, in imiquimod-treated rats, ASCT1 and SNAT2 protein was also decreased in male placentas, while EAAT2 was decreased in female placentas. CAT3 was increased in female fetal brains. Consistent with this, imiquimod altered amino acid levels in fetal brains, while RNAseq demonstrated changes in expression of several genes implicated in autism. Thus, imiquimod alters amino acid transporter levels in pregnant rats, and similar changes occur in human placentas during active infection. This suggests that changes in expression of amino acid transporters may contribute to effects mediated by MIA toward altered neurodevelopment.
- Open Access
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Brain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways
Finding effective disease‐modifying treatment for Alzheimer's disease remains challenging due to an array of factors contributing to the loss of neural function. The current study demonstrates a new strategy, using multitargeted bioactive nanoparticles to modify the brain microenvironment to achieve therapeutic benefits in a well‐characterized mouse model of Alzheimer's disease. The application of brain‐penetrating manganese dioxide nanoparticles significantly reduces hypoxia, neuroinflammation, and oxidative stress; ultimately reducing levels of amyloid β plaques within the neocortex. Analyses of molecular biomarkers and magnetic resonance imaging‐based functional studies indicate that these effects improve microvessel integrity, cerebral blood flow, and cerebral lymphatic clearance of amyloid β. These changes collectively shift the brain microenvironment toward conditions more favorable to continued neural function as demonstrated by improved cognitive function following treatment. Such multimodal disease‐modifying treatment may bridge critical gaps in the therapeutic treatment of neurodegenerative disease.
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Open AccessBrain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways
Finding effective disease‐modifying treatment for Alzheimer's disease remains challenging due to an array of factors contributing to the loss of neural function. The current study demonstrates a new strategy, using multitargeted bioactive nanoparticles to modify the brain microenvironment to achieve therapeutic benefits in a well‐characterized mouse model of Alzheimer's disease. The application of brain‐penetrating manganese dioxide nanoparticles significantly reduces hypoxia, neuroinflammation, and oxidative stress; ultimately reducing levels of amyloid β plaques within the neocortex. Analyses of molecular biomarkers and magnetic resonance imaging‐based functional studies indicate that these effects improve microvessel integrity, cerebral blood flow, and cerebral lymphatic clearance of amyloid β. These changes collectively shift the brain microenvironment toward conditions more favorable to continued neural function as demonstrated by improved cognitive function following treatment. Such multimodal disease‐modifying treatment may bridge critical gaps in the therapeutic treatment of neurodegenerative disease.
- 12 February 2022
- Published by Elsevier in Experimental Neurology
- Vol. 351, 114010
Cisplatin toxicity in the developing brain displays an absolute requirement for caspase-3
- 12 February 2022
- Published by Elsevier in Experimental Neurology
- Vol. 351, 114010
Cisplatin toxicity in the developing brain displays an absolute requirement for caspase-3
- 25 August 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (8) , 1727-1742
Necroptotic–Apoptotic Regulation in an Endothelin-1 Model of Cerebral Ischemia
The primary forms of cell death seen in ischemic stroke are of two major types: a necrotic/necroptotic form, and an apoptotic form that is frequently seen in penumbral regions of injury. Typically apoptotic versus necroptotic programmed cell death is described as competitive in nature, where necroptosis is often described as playing a backup role to apoptosis. In the present study, we examined the relationship between these two forms of cell death in a murine endothelin-1 model of ischemia–reperfusion injury in wildtype and caspase-3 null mice with and without addition of the pharmacologic RIPK1 phosphorylation inhibitor necrostatin-1. Analyses of ischemic brain injury were performed via both cellular and volumetric assessments, electron microscopy, TUNEL staining, activated caspase-3 and caspase-7 staining, as well as CD11b and F4/80 staining. Inhibition of caspase-3 or RIPK1 phosphorylation demonstrates significant neural protective effects which are non-additive and exhibit significant overlap in protected regions. Interestingly, morphologic analysis of the cortex demonstrates reduced apoptosis following RIPK1 inhibition. Consistent with this, RIPK1 inhibition reduces the levels of both caspase-3 and caspase-7 activation. Additionally, this protection appears independent of secondary inflammatory mediators. Together, these observations demonstrate that the necroptotic protein RIPK1 modifies caspase-3/-7 activity, ultimately resulting in decreased neuronal apoptosis. These findings thus modify the traditional exclusionary view of apoptotic/necroptotic signaling, revealing a new form of interaction between these dominant forms of cell death.
- 25 August 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 41 (8) , 1727-1742
Necroptotic–Apoptotic Regulation in an Endothelin-1 Model of Cerebral Ischemia
The primary forms of cell death seen in ischemic stroke are of two major types: a necrotic/necroptotic form, and an apoptotic form that is frequently seen in penumbral regions of injury. Typically apoptotic versus necroptotic programmed cell death is described as competitive in nature, where necroptosis is often described as playing a backup role to apoptosis. In the present study, we examined the relationship between these two forms of cell death in a murine endothelin-1 model of ischemia–reperfusion injury in wildtype and caspase-3 null mice with and without addition of the pharmacologic RIPK1 phosphorylation inhibitor necrostatin-1. Analyses of ischemic brain injury were performed via both cellular and volumetric assessments, electron microscopy, TUNEL staining, activated caspase-3 and caspase-7 staining, as well as CD11b and F4/80 staining. Inhibition of caspase-3 or RIPK1 phosphorylation demonstrates significant neural protective effects which are non-additive and exhibit significant overlap in protected regions. Interestingly, morphologic analysis of the cortex demonstrates reduced apoptosis following RIPK1 inhibition. Consistent with this, RIPK1 inhibition reduces the levels of both caspase-3 and caspase-7 activation. Additionally, this protection appears independent of secondary inflammatory mediators. Together, these observations demonstrate that the necroptotic protein RIPK1 modifies caspase-3/-7 activity, ultimately resulting in decreased neuronal apoptosis. These findings thus modify the traditional exclusionary view of apoptotic/necroptotic signaling, revealing a new form of interaction between these dominant forms of cell death.